Topline KARDIA-2 findings showed zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB.
The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.